Rapport Therapeutics, Inc. has reported a significant stock acquisition by its director, Paul M. Silva. On October 22, 2026, Silva acquired 3,680 shares of the company's common stock at a price of $27.075 per share. This transaction is noteworthy as it reflects Silva's confidence in the company's future prospects and growth potential.
Background
Rapport Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies. The company operates under the SIC classification of 2834, which pertains to Pharmaceutical Preparations. Rapport is traded on the Nasdaq under the ticker symbol RAPP. The company is categorized as an emerging growth company and is incorporated in Delaware.
What the Filing Says
The SEC filing indicates that Paul M. Silva, a director of Rapport Therapeutics, acquired 3,680 shares of common stock on October 22, 2026. The filing states, "Transaction Code: P, Transaction Amounts: 3680 shares, Transaction Price Per Share: 27.075." Following this transaction, Silva will own a total of 3,680 shares of the company.
Impact
This acquisition may influence various stakeholders, including investors and analysts, who often view insider purchases as a positive signal regarding a company's future. The pharmaceutical preparations industry may also take note, as insider transactions can reflect broader market sentiments and trends.
What's Next
The filing does not say what happens next.